Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Rahman, Michael Stratton (1998)The genetics of breast cancer susceptibility.
Annual review of genetics, 32
S. Seal, Deborah Thompson, A. Renwick, Anna Elliott, P. Kelly, R. Barfoot, T. Chagtai, H. Jayatilake, Munaza Ahmed, Katarina Spanova, B. North, L. McGuffog, D. Evans, D. Eccles, D. Easton, M. Stratton, N. Rahman, The Collaboration (2006)Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles
Nature Genetics, 38
Fan Zhang, Q. Fan, Keqin Ren, P. Andreassen (2009)PALB2 Functionally Connects the Breast Cancer Susceptibility Proteins BRCA1 and BRCA2
Molecular Cancer Research, 7
A. Menoyo, H. Alazzouzi, E. Espı́n, Manel Armengol, Hiroyuki Yamamoto, S. Schwartz (2001)Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.
Cancer research, 61 21
EM Bahassi, JL Ovesen, AL Riesenberg, WZ Bernstein, PE Hasty, PJ Stambrook (2008)The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage
K. Pylkäs, H. Erkko, J. Nikkilä, Szilvia Solyom, R. Winqvist (2008)Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families
BMC Cancer, 8
G. Zhi, James Wilson, Xiaoyong Chen, D. Krause, Yuxuan Xiao, N. Jones, G. Kupfer (2009)Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction.
Cancer research, 69 22
R. Litman, Min Peng, Zhe-Long Jin, Fan Zhang, Junran Zhang, S. Powell, P. Andreassen, Sharon Cantor (2005)BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ.
Cancer cell, 8 3
J. Guervilly, Gaëtane Macé-Aimé, F. Rosselli (2008)Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia.
Human molecular genetics, 17 5
P. Vahteristo, Kristiina Yliannala, A. Tamminen, H. Eerola, C. Blomqvist, H. Nevanlinna (2006)BACH1 Ser919Pro variant and breast cancer risk
BMC Cancer, 6
M. Allinen, L. Peri, S. Kujala, J. Lahti-Domenici, Kati Outila, S. Karppinen, V. Launonen, R. Winqvist (2002)Analysis of 11q21–24 loss of heterozygosity candidate target genes in breast cancer: Indications of TSLC1 promoter hypermethylation
F. Bertoni, A. Codegoni, D. Furlan, M. Tibiletti, C. Capella, M. Broggini (1999)CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers
S. Collis, L. Barber, A. Clark, JULIE Martin, Jordan Ward, S. Boulton (2007)HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability
Nature Cell Biology, 9
O. Hampton, P. Hollander, Christopher Miller, David Delgado, Jian Li, C. Coarfa, R. Harris, S. Richards, S. Scherer, D. Muzny, R. Gibbs, Adrian Lee, A. Milosavljevic (2009)A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome.
Genome research, 19 2
M. Stratton, N. Rahman (2007)The emerging landscape of breast cancer susceptibility
Nature Genetics, 40
S. Karppinen, J. Vuosku, K. Heikkinen, M. Allinen, R. Winqvist (2003)No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families.
European journal of cancer, 39 3
N. Haruki, H. Saito, Y. Tatematsu, H. Konishi, T. Harano, A. Masuda, H. Osada, Y. Fujii, T. Takahashi (2000)Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer.
Cancer research, 60 17
N. Ameziane, Ans Ouweland, M. Adank, R. Vijzelaar, A. Errami, J. Dorsman, H. Joenje, H. Meijers-Heijboer, Q. Waisfisz (2009)Lack of large genomic deletions in BRIP1, PALB2, and FANCD2 genes in BRCA1/2 negative familial breast cancer
Breast Cancer Research and Treatment, 118
T. Walsh, S. Casadei, Kathryn Coats, E. Swisher, S. Stray, Jake Higgins, Kevin Roach, Jessica Mandell, Ming Lee, S. Ciernikova, L. Foretova, P. Souček, M. King (2006)Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
JAMA, 295 12
Don Conroy, M. Shah, H. Munday, C. Jordan, B. Perkins, Judy West, Karen Redman, K. Driver, Morteza Aghmesheh, D. Amor, Lesley Andrews, Y. Antill, Jane Armes, Shane Armitage, Leanne Arnold, Rosemary Balleine, Glenn Begley, J. Beilby, Ian Bennett, Barbara Bennett, Geoffrey Berry, Anneke Blackburn, Meagan Brennan, Melissa Brown, Michael Buckley, J. Burke, Phyllis Butow, Keith Byron, David Callen, Ian Campbell, G. Chenevix-Trench, Christine Clarke, Alison Colley, Dick Cotton, Jisheng Cui, Bronwyn Culling, Margaret Cummings, Sarah-Jane Dawson, Joanne Dixon, Alexander Dobrovic, Tracy Dudding, Ted Edkins, M. Eisenbruch, G. Farshid, Susan Fawcett, Michael Field, Frank Firgaira, Jean Fleming, John Forbes, Michael Friedlander, Clara Gaff, Mac Gardner, M. Gattas, Peter George, G. Giles, G. Gill, Jack Goldblatt, Sian Greening, S. Grist, Eric Haan, Marion Harris, Stewart Hart, N. Hayward, J. Hopper, Evelyn Humphrey, Mark Jenkins, Alison Jones, R. Kefford, Judy Kirk, James Kollias, Sergey Kovalenko, Sunil Lakhani, Jennifer Leary, Jacqueline Lim, Geoff Lindeman, Lara Lipton, Lizz Lobb, Mariette Maclurcan, Graham Mann, Deb Marsh, M. Mccredie, Michael McKay, Sue-Anne McLachlan, Bettina Meiser, R. Milne, Gillian Mitchell, Beth Newman, Imelda O’Loughlin, Lester Peters, K. Phillips, Melanie Price, Jeanne Reeve, Tony Reeve, Gina Rinehart, Bridget Robinson, Elizabeth Salisbury, J. Sambrook, Christobel Saunders, C. Scott, Elizabeth Scott, Rodney Scott, Andrew Shelling, M. Southey, A. Spurdle, Graeme Suthers, Donna Taylor, Christopher Tennant, Heather Thorne, S. Townshend, Kathy Tucker, Janet Tyler, Deon Venter, J. Visvader, Ian Walpole, Robin Ward, Paul Waring, Bev Warner, Graham Warren, Elizabeth Watson, Rachael Williams, Judy Wilson, Ingrid Winship, Adele Green, Dorota Gertig, Penny Webb (2007)Genome-wide association study identifies novel breast cancer susceptibility loci
J. Puc, M. Keniry, Hong Li, T. Pandita, A. Choudhury, L. Memeo, M. Mansukhani, V. Murty, Z. Gaciong, S. Meek, H. Piwnica-Worms, H. Hibshoosh, R. Parsons (2005)Lack of PTEN sequesters CHK1 and initiates genetic instability.
Cancer cell, 7 2
AnglianBreastCancerStudy Group (2000)Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases
Br J Cancer, 83
Sharon Cantor, R. Drapkin, Fan Zhang, Yafang Lin, Juliana Han, S. Pamidi, D. Livingston (2004)The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.
Proceedings of the National Academy of Sciences of the United States of America, 101 8
R. Yarden, S. Pardo-Reoyo, M. Sgagias, K. Cowan, L. Brody (2002)BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage
Nature Genetics, 30
F. Depontieu, B. Grigoriu, A. Scherpereel, E. Adam, M. Delehedde, P. Gosset, P. Lassalle (2008)Loss of Endocan tumorigenic properties after alternative splicing of exon 2
BMC Cancer, 8
T. Papp, A. Niemetz, Nils Dosdahl, Krishan Kumar, D. Schiffmann (2007)Mutational analysis of Chk1, Chk2, Apaf1 and Rb1 in human malignant melanoma cell lines.
Oncology reports, 17 1
O. Levran, C. Attwooll, R. Henry, K. Milton, K. Neveling, P. Río, S. Batish, R. Kalb, E. Velleuer, S. Barral, J. Ott, J. Petrini, D. Schindler, H. Hanenberg, A. Auerbach (2005)The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia
Nature Genetics, 37
P. Vahteristo, A. Tamminen, Petteri Karvinen, H. Eerola, C. Eklund, L. Aaltonen, C. Blomqvist, K. Aittomäki, H. Nevanlinna (2001)p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Cancer research, 61 15
Sharon Cantor, D. Bell, S. Ganesan, Elizabeth Kass, R. Drapkin, S. Grossman, D. Wahrer, D. Sgroi, William Lane, D. Haber, D. Livingston (2001)BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function
Xiaozhe Wang, R. Kennedy, Kallol Ray, P. Stuckert, T. Ellenberger, A. D’Andrea (2007)Chk1-Mediated Phosphorylation of FANCE Is Required for the Fanconi Anemia/BRCA Pathway
Molecular and Cellular Biology, 27
Anna Marsh, S. Healey, Aaron Lewis, A. Spurdle, M. Kedda, K. Khanna, G. Mann, G. Pupo, S. Lakhani, G. Chenevix-Trench, kConFab (2006)Mutation analysis of five candidate genes in familial breast cancer
Breast Cancer Research and Treatment, 105
A. Efeyan, M. Serrano (2007)p53: Guardian of the Genome and Policeman of the Oncogenes
Cell Cycle, 6
C. Kim, J. Lee, J. Song, Y. Cho, S. Kim, S. Nam, N. Yoo, W. Park, J. Lee (2007)Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 33 5
T. Stracker, Takehiko Usui, J. Petrini (2009)Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response.
DNA repair, 8 9
Krishan Kumar, Q. Rahman, H. Schipper, C. Matschegewski, D. Schiffmann, T. Papp (2005)Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines.
Oncology reports, 14 3
N. Ting, Wen-Hwa Lee (2004)The DNA double-strand break response pathway: becoming more BRCAish than ever.
DNA repair, 3 8-9
M. Levitus, Q. Waisfisz, B. Godthelp, Y. Vries, S. Hussain, W. Wiegant, Elhaam Elghalbzouri-Maghrani, Jûrgen Steltenpool, M. Rooimans, G. Pals, F. Arwert, C. Mathew, M. Zdzienicka, K. Hiom, J. Winter, H. Joenje (2005)The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J
Nature Genetics, 37
Shirley Sy, M. Huen, Junjie Chen (2009)PALB2 is an integral component of the BRCA complex required for homologous recombination repair
Proceedings of the National Academy of Sciences, 106
R. Wooster, B. Weber (2003)Breast and ovarian cancer.
The New England journal of medicine, 348 23
In search for susceptibility genes that could explain an additional portion of familial breast cancer clustering in Finland, we set out to evaluate the presence of large genomic rearrangements in two candidate genes, BRIP1 and CHK1. BRIP1 is a BRCA1 associated protein that is mutated in a fraction of familial breast cancer and Fanconi anemia cases. To date, the role of large BRIP1 deletions in breast cancer susceptibility is not well-characterized. CHK1 is a critical maintainer of cell cycle checkpoints and genomic stability, and is also involved in the BRCA1 and FA protein signalling pathways. Although CHK1 is a very important protein for cell cycle and DNA integrity maintenance control, no mutations in this gene has yet been associated with predisposition to cancer. For the present study, blood DNA from affected index persons of 111 Northern Finnish breast cancer families was assessed for possible constitutional exonic deletions or amplifications in the BRIP1 and CHK1 genes by using the multiplex ligation-dependent probe amplification method. Our results showed that exonic deletions or amplifications affecting the BRIP1 and CHK1 genes seem not to contribute to hereditary breast cancer susceptibility in the Finnish population. To our knowledge, this is the first attempt to determine the existence of large CHK1 deletions in familial breast cancer or in any disease with a hereditary background.
Familial Cancer – Springer Journals
Published: Jun 22, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.